Text Size

Treatment of AIDS Vacuolar Myelopathy With Methionine

This study has been completed.
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier:
NCT00032695
First received: March 28, 2002
Last updated: May 12, 2006
Last verified: November 2005
History of Changes
  Purpose

The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.


Condition Intervention Phase
Myelopathy
AIDS-Myelopathy
AIDS Vacuolar Myelopathy
 Drug: methionine
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Estimated Enrollment: 56
Detailed Description:

Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Between 18 and 80 years of age

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00032695

Locations
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Alessandro Di Rocco, MD
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00032695     History of Changes
Other Study ID Numbers: R01NS35745
Study First Received: March 28, 2002
Last Updated: May 12, 2006
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
myelopathy
AIDS-myelopathy
AIDS vacuolar myelopathy
methionine

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Bone Marrow Diseases
Spinal Cord Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Hematologic Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 22, 2013